Free Trial

Twinbeech Capital LP Increases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Ultragenyx Pharmaceutical logo with Medical background

Twinbeech Capital LP increased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 531.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,857 shares of the biopharmaceutical company's stock after purchasing an additional 28,497 shares during the quarter. Twinbeech Capital LP's holdings in Ultragenyx Pharmaceutical were worth $1,424,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Van ECK Associates Corp increased its position in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 273 shares during the period. BOKF NA increased its position in shares of Ultragenyx Pharmaceutical by 5.0% in the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock valued at $336,000 after acquiring an additional 382 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the period. Arizona State Retirement System increased its position in shares of Ultragenyx Pharmaceutical by 2.4% in the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock valued at $1,011,000 after acquiring an additional 568 shares during the period. Finally, Guggenheim Capital LLC increased its position in shares of Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 45,222 shares of the biopharmaceutical company's stock valued at $1,902,000 after acquiring an additional 670 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock traded up $0.14 during midday trading on Tuesday, reaching $35.80. 171,165 shares of the company traded hands, compared to its average volume of 824,083. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of -5.65 and a beta of 0.34. The business has a 50 day moving average of $35.97 and a two-hundred day moving average of $41.01. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same period in the prior year, the company posted ($2.03) earnings per share. The firm's quarterly revenue was up 28.0% on a year-over-year basis. As a group, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analysts Set New Price Targets

RARE has been the topic of a number of analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Piper Sandler dropped their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. HC Wainwright reiterated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Canaccord Genuity Group upped their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $90.93.

Get Our Latest Research Report on Ultragenyx Pharmaceutical

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 25,000 shares of the company's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,158,985 shares of the company's stock, valued at approximately $91,713,682.80. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the sale, the executive vice president now directly owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This represents a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 125,405 shares of company stock valued at $5,285,169. Insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

See Also

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.

While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines